Colorectal Cancer | Specialty

Dr Hitchins on the Association Between Constitutional MLH1 Methylation and MRD in Select Cancers

August 15th 2023

Megan Hitchins, PhD, discusses results from an analysis on the prevalence of high-risk constitutional MLH1 methylation in early-onset colorectal and endometrial cancers displaying mismatch repair deficiency.

BDC-1001 Monotherapy Under Further Evaluation in Phase 2 Trial in HER2+ Cancers

August 11th 2023

The first patients have been dosed in the phase 2 portion of a phase 1/2 trial evaluating BDC-1001 monotherapy in patients with HER2-positive colorectal cancer, endometrial cancer, and gastroesophageal cancer.

Dr Hays on Unmet Needs in CRC

August 10th 2023

John L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.

Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRC

August 4th 2023

Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.

Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors

August 2nd 2023

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC

August 2nd 2023

FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer

August 2nd 2023

The FDA has approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; a VEGF inhibitor; and an EGFR inhibitor, if they have RAS wild-type disease.

Franklin on the Investigation of Social Needs and Screening Rates in CRC

August 1st 2023

Isabelle Franklin, discusses the investigation of the correlation between self-reported social needs and colorectal cancer screening.

ERASur Study Evaluates Total Ablative Therapy Plus Systemic Treatment in mCRC

August 1st 2023

The safety and efficacy of adding total ablative therapy of all disease sites to standard systemic treatment is being investigated in patients with limited metastatic colorectal cancer as part of the ongoing phase 3 ERASur study.

Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRC

July 31st 2023

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer

Molecular Testing Drives Progress in CRC

July 31st 2023

Emerging strategies leveraging biomarker data for the treatment of patients with early-stage and metastatic colorectal cancer have made precision medicine a top-of-mind topic for gastrointestinal oncologists.

Future Perspectives on HER2+ Metastatic Colorectal Cancer

July 28th 2023

Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.

Social Determinants of Health Correlate With Lower CRC Screening Rates

July 26th 2023

Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening, expands on how these social determinants of health could affect a patient’s likelihood of adhering to screening guidelines, and highlights ways to potentially address these barriers to screening.

Dr Grieb on the Need for Novel Biomarkers in CRC

July 26th 2023

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

July 26th 2023

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Treatment of Refractory Metastatic Colorectal Cancer: The Phase 3 Randomized SUNLIGHT Study

July 25th 2023

Marwan G. Fakih, MD, reviews data from the phase 3 randomized SUNLIGHT trial investigating trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.

DESTINY-CRC02: Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer

July 21st 2023

An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.

Evolving Treatment Landscape in Metastatic Colorectal Cancer

July 21st 2023

Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.

Dr Andre on the SOLSTICE Trial in mCRC

July 21st 2023

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC

July 19th 2023

Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.